Related Experiment Video
Updated: Feb 1, 2026
07:13
A Rat Model of Pressure Overload Induced Moderate Remodeling and Systolic Dysfunction as Opposed to Overt Systolic Heart Failure
Published on: April 30, 2020
6.9K
Cardio-omentopexy Reduces Cardiac Fibrosis and Heart Failure After Experimental Pressure Overload
Jian Wang1, Qing-Jun Zhang2, Timothy J Pirolli1
1Department of Thoracic and Cardiovascular Surgery, University of Texas Southwestern Medical Center, Dallas, Texas.
The Annals of Thoracic Surgery
|December 16, 2018
Summary
Cardio-omentopexy significantly improved heart function in a rat model of left ventricular hypertrophy (LVH). This procedure reduced cardiac dilation, improved contractility, and decreased fibrosis, offering a potential therapeutic strategy for heart disease.
Area of Science:
- Cardiovascular Surgery
- Regenerative Medicine
- Cardiac Physiology
Background:
- The pedicled greater omentum shows promise in treating ischemic heart disease.
- The efficacy of cardio-omentopexy in pressure overload-induced left ventricular hypertrophy (LVH) remains unexplored.
Purpose of the Study:
- To investigate the impact of cardio-omentopexy on a rat model of LVH.
- To assess the effects of omentopexy on cardiac structure, function, and molecular markers in LVH.
Main Methods:
- Left ventricular hypertrophy (LVH) was induced in rats by ascending aortic banding.
- Survivors underwent either cardio-omentopexy or sham surgery.
- Echocardiography, gene expression, and histological analyses were performed 10 weeks post-procedure.
Main Results:
- Cardio-omentopexy significantly reduced LV end-systolic diameter, cardiomyocyte size, and myocardial fibrosis compared to controls.
- LV ejection fraction was preserved in the cardio-omentopexy group.
- Myocardial capillary density was increased, and fibrotic markers were decreased post-omentopexy.
Conclusions:
- Cardio-omentopexy effectively mitigated cardiac dilation, contractile dysfunction, and fibrosis in a pressure overload LVH model.
- The procedure maintained molecular indicators of cardiac contractile function.
- Omentopexy presents a potential therapeutic approach for managing LVH.
Related Concept Videos
01:29Heart Failure II: Pathophysiology
920
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
920
01:17Pathophysiology of Heart Failure
3.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.6K
01:27Heart Failure I: Introduction
882
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
882
01:22Heart Failure VI: Adjunct Therapies
336
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
336
01:22Heart Failure Drugs: Diuretics
966
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
966
01:30Heart Failure V: Medical Management
312
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
312